keyword
MENU ▼
Read by QxMD icon Read
search

Ceftaroline

keyword
https://www.readbyqxmd.com/read/28720485/ceftaroline-modulates-the-innate-immune-and-host-defense-responses-of-immunocompetent-cells-exposed-to-cigarette-smoke
#1
A Bruno, C Cipollina, S Di Vincenzo, L Siena, P Dino, F Di Gaudio, M Gjomarkaj, E Pace
BACKGROUND: Cigarette smoke, the principal risk factor for chronic obstructive pulmonary disease (COPD), negatively influences the effectiveness of the immune system's response to a pathogen. The antibiotic ceftaroline exerts immune-modulatory effects in bronchial epithelial cells exposed to cigarette smoke. AIMS AND METHODS: The present study aims to assess the effects of ceftaroline on TLR2 and TLR4 expression, LPS binding and TNF-α and human beta defensin (HBD2) release in an undifferentiated and PMA-differentiated human monocyte cell line (THP-1) exposed or not to cigarette smoke extracts (CSE)...
July 15, 2017: Toxicology Letters
https://www.readbyqxmd.com/read/28705799/rapid-developing-empyema-by-group-f-beta-streptococcus-anginosus-group
#2
Muhammad Azharuddin, Dy Prudence, Prem Shanker Shukla, Ajay Mathur
A 43-year-old male had progressive pleuritic left-sided chest tightness with shortness of breath. He had dental caries and tenderness on palpation of the left lateral chest. Complete blood count showed leucocytosis. CT scan of the chest with pulmonary emboli protocol showed multiple pulmonary nodules and nodular pleural thickening at left posterior lateral pleura. Forty-eight hours post CTPE scan, CT scan of the chest, abdomen and pelvis displayed right lower lobe consolidation and left-sided pleural effusion with superimposed compressive atelectasis...
July 13, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28702467/ceftaroline-for-severe-methicillin-resistant-staphylococcus-aureus-infections-a-systematic-review
#3
REVIEW
Reese A Cosimi, Nahal Beik, David W Kubiak, Jennifer A Johnson
Ceftaroline is approved by the Food and Drug Administration for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia, including cases with concurrent bacteremia. Use for serious methicillin-resistant Staphylococcus aureus (MRSA) infections has risen for a multitude of reasons. The aim of this article is to review the literature evaluating clinical outcomes and safety of ceftaroline prescribed for serious MRSA infections. We conducted a literature search in Ovid (Medline) and PubMed for reputable case reports, clinical trials, and reviews focusing on the use of ceftaroline for treatment of MRSA infections...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28697650/ceftaroline-for-the-treatment-of-osteomyelitis-caused-by-methicillin-resistant-staphylococcus-aureus-a-case-series
#4
Karineh Lalikian, Rita Parsiani, Regina Won, Eric Chang, R Brigg Turner
Despite limited clinical data, ceftaroline is commonly used for treatment of complicated, invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA). A retrospective chart review was conducted of adult patients receiving ceftaroline for MRSA osteomyelitis admitted between April 2011 and March 2016 at a five-hospital system. Twelve patients met the inclusion criteria. All patients received prior antimicrobial therapy with a median time to switch to ceftaroline of 45.5 days. Five of the 12 patients (41...
July 11, 2017: Journal of Chemotherapy
https://www.readbyqxmd.com/read/28666751/recently-approved-antibacterials-for-mrsa-and-other-gram-positive-pathogens-the-shock-of-the-new
#5
REVIEW
Michael Z David, Matthew Dryden, Thomas Gottlieb, Pierre Tattevin, Ian M Gould
A number of novel antimicrobial drugs with activity against Gram positive bacterial pathogens have been licensed in the past four years. These drugs have the potential to enrich the group of intravenous drugs already available that are in common use against methicillin resistant Staphylococcus aureus, vancomycin resistant Enterococcus, and other antibiotic resistant Gram positive pathogens. The advantages and disadvantages of these drugs are not yet fully realized. Here we review the five most promising newly approved compounds: ceftaroline, ceftobiprole, oritavancin, dalbavancin and tedizolid...
June 27, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28664412/early-use-of-ceftaroline-fosamil-in-the-united-states-veterans-health-care-system
#6
Rachel S Britt, Kirk E Evoy, Grace C Lee, Kelly R Reveles, Kimberly M Sorensen, Xavier Jones, Mary Bollinger, Christopher R Frei
BACKGROUND: Ceftaroline fosamil is US Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, but it is not known how ceftaroline is being used in real-world settings or how adverse effects (AEs) and mortality compare to clinical trials. OBJECTIVE: This study describes ceftaroline use, AEs, and mortality in US Veterans Health Administration (VHA) hospital patients. METHODS: This phase IV, population-based, epidemiologic study analyzed patients ≥18 years old who received one or more ceftaroline doses within 14 days of admission to 69 VHA hospitals in 41 US states/territories from 1 October 2010 to 30 September 2014...
June 29, 2017: Drugs
https://www.readbyqxmd.com/read/28642145/new-and-improved-a-review-of-novel-antibiotics-for-gram-positive-bacteria
#7
REVIEW
Mohamed Abbas, Mical Paul, Angela Huttner
BACKGROUND: The number of antibiotics in the pipeline targeting Gram-positive pathogens has increased in recent years. AIMS: This narrative review aims to provide a summary of existing evidence on efficacy, microbiologic spectrum, and safety of novel systemic antibiotics that have either recently been licenced or completed phase III trials, and possess activity predominantly against Gram-positive organisms. SOURCES: A review of the published literature via the MEDLINE database was performed...
June 19, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28630196/antimicrobial-susceptibility-trends-among-staphylococcus-aureus-from-united-states-hospitals-results-from-7-years-of-the-ceftaroline-aware-surveillance-program-2010-2016
#8
Helio S Sader, Rodrigo E Mendes, Jennifer M Streit, Robert K Flamm
We evaluated trends in Staphylococcus aureus antimicrobial susceptibility in United States hospitals in the 2010-2016 period. A total of 21,056 clinical isolates from 42 medical centers were tested for susceptibility by broth microdilution methods. MRSA rates decreased from 50.0% (2010) to 42.2% (2016). Susceptibility to erythromycin, levofloxacin, and clindamycin increased slightly, whereas susceptibility to ceftaroline, trimethoprim-sulfamethoxazole, and tetracycline remained stable. Ceftaroline retained potent activity against MSSA and MRSA (97...
June 19, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28600216/molecular-epidemiology-and-antibiotic-resistance-of-methicillin-resistant-staphylococcus-aureus-circulating-in-the-russian-federation
#9
Vladimir Gostev, Alexander Kruglov, Olga Kalinogorskaya, Olga Dmitrenko, Olga Khokhlova, Tatsuo Yamamoto, Yuri Lobzin, Irina Ryabchenko, Sergey Sidorenko
The aim of this study was to investigate the patterns of antimicrobial resistance and molecular features of methicillin-resistant Staphylococcus aureus (MRSA) isolates in Russia. Isolates recovered from hospital patients (n=480), healthy medical personnel (n=25), and healthy carriers (n=13) were included in the study. Hospital-acquired MRSA (HA-MRSA) demonstrated high resistance to ciprofloxacin, gentamicin, and chloramphenicol (76%-92%), moderate - to tetracycline, erythromycin, clindamycin, and rifampicin (38%-54%), and low - to fusidic acid, co-trimoxazole, mupirocin, and daptomycin (2%-7%)...
June 7, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/28599867/macrolide-therapy-for-community-acquired-pneumonia-due-to-atypical-pathogens-outcomes-assessment-at-an-early-time-point
#10
Thomas M File, Paul B Eckburg, George H Talbot, Lily Llorens, H David Friedland
BACKGROUND: Therapy directed against atypical pathogens in patients with community-acquired pneumonia (CAP) is often recommended. This post-hoc analysis evaluated the effect of addition of a macrolide to ceftaroline fosamil or ceftriaxone treatment in atypical CAP. METHODS: Two phase 3, double-blind, comparative safety and efficacy studies of ceftaroline fosamil vs. ceftriaxone, FOCUS 1 and FOCUS 2, enrolled adults with CAP. Only FOCUS 1 included 24-h adjunctive clarithromycin therapy for all patients on day 1...
June 6, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28559260/an-unusual-e-coli-pbp3-insertion-sequence-identified-from-a-collection-of-carbapenem-resistant-enterobacteriaceae-cre-tested-in-vitro-with-ceftazidime-ceftaroline-or-aztreonam-avibactam-combinations
#11
Yunliang Zhang, Ankita Kashikar, C Adam Brown, Gerald Denys, Karen Bush
Carbapenemase-producing Enterobacteriaceae isolates (n=110) from healthcare centers in central Indiana (2010-2013) were tested for susceptibility to combinations of avibactam (4 μg/ml) with ceftazidime, ceftaroline or aztreonam. MIC50/MIC90 values were 1/2 μg/ml (ceftazidime-avibactam), 0.5/2 μg/ml (ceftaroline-avibactam) and 0.25/0.5 μg/ml (aztreonam-avibactam.) A β-lactam MIC of 8 μg/ml was reported for the three combinations against one Escherichia coli isolate with an unusual TIPY insertion following Tyr344 in penicillin-binding protein 3 (PBP3) as the result of gene duplication...
May 30, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28505331/antimicrobial-susceptibility-of-clinical-isolates-of-neisseria-gonorrhoeae-to-alternative-antimicrobials-with-therapeutic-potential
#12
P R S Lagacé-Wiens, H J Adam, N M Laing, M R Baxter, I Martin, M R Mulvey, J A Karlowsky, D J Hoban, G G Zhanel
Background: The prevalence of MDR Neisseria gonorrhoeae is increasing globally and represents a public health emergency. Development and approval of new anti-gonococcal agents may take years. As a concurrent approach to developing new antimicrobials, the laboratory and clinical evaluation of currently licensed antimicrobials not widely used for the treatment of gonorrhoea may provide new options for the treatment of gonococcal infections. Objectives: To determine the in vitro activity of nine alternative, currently licensed and late-development antimicrobials with the potential to treat gonococcal infections against 112 clinical isolates of N...
May 12, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28483961/efficacy-of-ceftaroline-against-methicillin-susceptible-staphylococcus-aureus-exhibiting-the-cefazolin-high-inoculum-effect-in-a-rat-model-of-endocarditis
#13
Kavindra V Singh, Truc T Tran, Esteban C Nannini, Vincent H Tam, Cesar A Arias, Barbara E Murray
Certain Staphylococcus aureus strains exhibit an inoculum effect (InE) with cefazolin (CFZ) that has been associated with therapeutic failures in high-inoculum infections. We assessed the in vitro activities of ceftaroline (CPT), CFZ, and nafcillin (NAF) against 17 type A β-lactamase (βla)-producing, methicillin-susceptible S. aureus (MSSA) strains, including the previously reported TX0117, which exhibits the CFZ InE, and its βla-cured derivative, TX0117c. Additionally, we determined the pharmacokinetics of CPT in rats after single intramuscular doses of 20 and 40 mg/kg of body weight and evaluated the activities of CPT (40 mg/kg every 8 h [q8h]), CFZ, and NAF against TX0117 and TX0117c in a rat model of infective endocarditis...
July 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28475731/evaluation-of-daptomycin-combinations-with-cephalosporins-or-gentamicin-against-streptococcus-mitis-group-strains-in-an-in-vitro-model-of-simulated-endocardial-vegetations-sevs
#14
Juwon Yim, Jordan R Smith, Nivedita B Singh, Seth Rice, Kyle Stamper, Cristina Garcia de la Maria, Arnold S Bayer, Nagendra N Mishra, José M Miró, Truc T Tran, Cesar A Arias, Paul Sullam, Michael J Rybak
Objectives: Among viridans group streptococcal infective endocarditis (IE), the Streptococcus mitis group is the most common aetiological organism. Treatment of IE caused by the S. mitis group is challenging due to the high frequency of β-lactam resistance, drug allergy and intolerability of mainstay antimicrobial agents such as vancomycin or gentamicin. Daptomycin has been suggested as an alternative therapeutic option in these scenarios based on its excellent susceptibility profile against S...
May 5, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28419033/oral-only-linezolid-rifampin-is-highly-effective-compared-with-other-antibiotics-for-periprosthetic-joint-infection-study-of-a-mouse-model
#15
John M Thompson, Vikram Saini, Alyssa G Ashbaugh, Robert J Miller, Alvaro A Ordonez, Roger V Ortines, Yu Wang, Robert S Sterling, Sanjay K Jain, Lloyd S Miller
BACKGROUND: The medical treatment of periprosthetic joint infection (PJI) involves prolonged systemic antibiotic courses, often with suboptimal clinical outcomes including increased morbidity and health-care costs. Oral and intravenous monotherapies and combination antibiotic regimens were evaluated in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) PJI. METHODS: Oral linezolid with or without oral rifampin, intravenous vancomycin with oral rifampin, intravenous daptomycin or ceftaroline with or without oral rifampin, oral doxycycline, or sham treatment were administered at human-exposure doses for 6 weeks in a mouse model of PJI...
April 19, 2017: Journal of Bone and Joint Surgery. American Volume
https://www.readbyqxmd.com/read/28407067/evaluation-of-a-second-sign-process-for-antimicrobial-prior-authorization
#16
Aimee M Dassner, Jennifer E Girotto
Background.: A second-sign prospective restriction of select broad-spectrum antimicrobials was fully implemented in January 2015 as a pediatric antimicrobial stewardship program (ASP) initiative to help ensure the most appropriate empiric use of ceftaroline, cefepime, fidaxomicin, linezolid, and vancomycin (intravenous). The objective of this evaluation is to assess the effectiveness of a forced second-sign process in the electronic medical record as a pediatric ASP strategy. We anticipated that the second-sign process for antibiotics would increase the appropriateness of empiric antibiotic use, as defined by preapproved criteria, clinical pathways, national guidelines, and pediatric-specific infectious diseases reference texts, while not causing significant delay in the initial administration of antibiotic therapy...
April 12, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/28403050/ceftaroline-activity-tested-against-bacterial-isolates-causing-community-acquired-respiratory-tract-infections-and-skin-and-skin-structure-infections-in-pediatric-patients-from-united-states-hospitals-2012-2014
#17
MULTICENTER STUDY
Michael A Pfaller, Rodrigo E Mendes, Mariana Castanheira, Robert K Flamm, Ronald N Jones, Helio S Sader
Ceftaroline fosamil has recently received US Food and Drug Administration approval for treatment of acute bacterial skin/skin structure infections (SSSIs), including those caused by methicillin-resistant Staphylococcus aureus and community-acquired bacterial pneumonia for pediatric patients ≥2 months old. We evaluated the potency and spectrum of ceftaroline and comparators when tested against community-acquired respiratory tract infection (CARTI) and SSSI pathogens from pediatric patients. A total of 3141 consecutive, unique pediatric patient isolates of clinical significance (1460 CARTI and 1681 SSSI isolates) were collected from 29 US medical centers and tested for susceptibility to ceftaroline and comparators by broth microdilution methods...
May 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28382572/current-clinical-trials-on-the-use-of-ceftaroline-in-the-pediatric-population
#18
REVIEW
Adam Corey, Tsz-Yin So
The rate of antibiotic resistance in children continues to rise requiring the use of new antibiotics. Ceftaroline fosamil, a newer-generation cephalosporin, was recently approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in children aged >2 months. Ceftaroline provides coverage against staphylococcal and streptococcal infections, including methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae...
April 5, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28373193/high-level-resistance-of-staphylococcus-aureus-to-%C3%AE-lactam-antibiotics-mediated-by-penicillin-binding-protein-4-pbp4
#19
Stephanie M Hamilton, J Andrew N Alexander, Eun Ju Choo, Li Basuino, Thaina M da Costa, Anatoly Severin, Marilyn Chung, Sandra Aedo, Natalie C J Strynadka, Alexander Tomasz, Som S Chatterjee, Henry F Chambers
Penicillin-binding protein 4 (PBP4), a nonessential, low-molecular-weight penicillin-binding protein of Staphylococcus aureus, has been implicated in low-level resistance to β-lactam antibiotics, although the mechanism is unknown. Mutations in PBP4 and its promoter were identified in a laboratory-generated mutant strain, CRB, which expresses high-level resistance to β-lactams, including resistance to the new-generation cephalosporins active against methicillin-resistant strains of S. aureus These mutations did not appreciably alter the β-lactam antibiotic binding affinity of purified recombinant mutant PBP4 compared to that of wild-type PBP4...
June 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28348157/exploring-the-landscape-of-diazabicyclooctane-dbo-inhibition-avibactam-inactivation-of-per-2-%C3%AE-lactamase
#20
Melina Ruggiero, Krisztina M Papp-Wallace, Magdalena A Taracila, Maria F Mojica, Christopher R Bethel, Susan D Rudin, Elise T Zeiser, Gabriel Gutkind, Robert A Bonomo, Pablo Power
PER β-lactamases are an emerging family of extended-spectrum β-lactamases (ESBL) found in Gram-negative bacteria. PER β-lactamases are unique among class A enzymes as they possess an inverted omega (Ω) loop and extended B3 β-strand. These singular structural features are hypothesized to contribute to their hydrolytic profile against oxyimino-cephalosporins (e.g., cefotaxime and ceftazidime). Here, we tested the ability of avibactam (AVI), a novel non-β-lactam β-lactamase inhibitor to inactivate PER-2...
June 2017: Antimicrobial Agents and Chemotherapy
keyword
keyword
21356
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"